Vol. 17/No. 16

James C. Yao, MD, discusses developments in the field of neuroendocrine tumors.

Although researchers have been exploring gene editing for more than 40 years, scientists say the CRISPR technology offers game-changing methods for anticancer research as well as a host of other applications.

Christina M. Annunziata, MD, PhD, has been instrumental in the genomic profiling of ovarian cancers and in elucidating the molecular pathways that are central to this disease.

Genome sequencing studies have uncovered an array of distinct genomic drivers underlying various ovarian cancer subtypes. If researchers can capitalize on these discoveries, it may offer a path to more individualized and effective treatment options.

With several more melanoma treatments poised to emerge from the pipeline, data on the optimal way to incorporate these novel drugs into practice lag far behind the breakneck pace of approvals.

To discover targeted therapies for the more common and severe types of medulloblastoma, a laboratory at Sanford Burnham Prebys Medical Discovery Institute has led efforts to develop genetically engineered mouse models and patient-derived xenografts for studying the molecular basis of the disease.

Even under the best of circumstances, the CRISPR gene-editing technology that we explore in this issue of OncologyLive won’t make it into clinical practice any time soon.

Although chemotherapy has changed dramatically since it was introduced, platinum-containing combinations remain standard in ovarian cancer. Often, the established regimen can be modified for patients who quite justifiably may fear the toxicities of platinum agents.